Italian XEN-Glaucoma Treatment Registry (XEN-GTR): Effectiveness and Safety at 36 Months of XEN45 Implant Authors: Francesco Oddone, Gloria Roberti, Sara Giammaria, Chiara Posarelli, Leonardo Mastropasqua, Luca Agnifili, Tommaso Micelli Ferrari, Vincenzo Pace, Matteo Sacchi, Romeo Altafini, Gianluca Scuderi, Andrea Perdicchi, Carmela Carnevale, Antonio Fea, Michele Figus, Eun Ji Lee Published: 2024 ABSTRACT AbstractObjectives: We evaluated the 3-year effectiveness and safety of XEN45, combined or not with phacoemulsification, in patients from the Italian XEN-Glaucoma Treatment Registry. Methods: Data from glaucoma patients who underwent XEN45 alone or combined with phacoemulsification were analyzed. Changes in intraocular pressure (IOP) and the number of ocular hypotensive medications (OHMs) were tested with repeated measures ANOVA in last observation carried forward (LOCF) and per-protocol (PP) analyses. Complete and qualified success (IOP < 18 mmHg and ≥20% IOP reduction from baseline, without or with OHMs) at 36 months and pre- and intraoperative factors predicting surgery failure were explored using survival analysis and Cox proportional-hazard models. Complications rates were evaluated to assess safety. Results: The analysis included 239 eyes (239 patients): 144 (60.2%) in the XEN alone and 95 (39.8%) in the XEN+Phaco groups. Overall success was achieved in 164 (68.1%) eyes [113 (68.9%) complete and 51 (31.1%) qualified], without significant differences in success (p = 0.07) and survival rates (p = 0.46) between groups. At the 36th month, the baseline IOP decreased from a median (IQR) of 23.0 (20.0–26.0) to 15.0 (12.0–17.5) mmHg (p < 0.01), with an overall 34.1 ± 20.1% IOP reduction. The mean ± SD number of OHMs decreased from the baseline of 2.7 ± 0.9 to 0.9 ± 1.1 at month 36 (p < 0.01). PP and LOCF analyses were comparable. Neither pre- nor intraoperative factors were significantly predictive of surgery failure. In 91 (38.1%) and 57 (23.8%) of the eyes, at least one postoperative complication occurred early (2 mmHg, was recorded. Visual acuity in decimals, the number of ocular hypotensive medications (OHMs), as well as complications and additional procedures were also recorded. 2.1. Surgical Technique XEN45 implant is composed of glutaraldehyde-crosslinked porcine gelatin, with dimensions of 45 μm for the inner lumen, 150 μm for the external diameter, and 6 mm for length. A 0.1 mL injection of mitomycin C (MMC) at a dosage of 0.2 mg/mL was given under the conjunctiva prior to the start of the procedure. The XEN45 was inserted via the trabecular meshwork using a 27-gauge preloaded injector to create an artificial connection between the anterior chamber and the subconjunctival region. One experienced glaucoma surgeon per center, who had performed at least ten XEN45 implants, performed all the internal implants. When appropriate, the XEN45 implant procedure was combined with phacoemulsification. Because the XEN-GTR is a real-world based registry, study centers did not standardize the surgical technique; therefore, decisions on the position of the implant site and the type of surgery (combined or not in accordance with the patients’ eye characteristics) were left to each surgeon, as well as the postoperative management. 2.2. Statistical Analysis The statistical analysis was conducted on the whole group of patients and separately for the XEN alone (eyes that underwent XEN45 implantation alone) and XEN+Phaco (eyes that underwent XEN45 implantation combined with phacoemulsification) groups. The analysis was carried out following the recent recommendations of the European Glaucoma Society—A guide on surgical innovation for glaucoma [6]. The proportion of patients identified as surgical success after three years of follow-up served as the main outcome measure. The criteria for success included the following: IOP < 18 mmHg and IOP decrease ≥ 20% at 36 months, with (qualified success) or without OHMs (complete success). The total number of eyes that achieved qualified and complete successes indicated the overall success. Failure was defined as an IOP of >18 mmHg in two consecutive follow-up visits, an IOP reduction < 20% at month 36, further glaucoma surgery or surgical revision, or clinical hypotony (IOP < 6 mmHg and ≥2 lines of visual acuity loss after month 1). An IOP > 18 mmHg in the first follow-up month was not considered a failure criterion. The open-source R (version 3.6.0) [7] with survival (version 3.2-7) [8] and survminer (version 0.4.9) [9] packages were used for statistical analysis. Medians and interquartile ranges (IQRs) and numbers (%) were used to summarize continuous variables and categorical variables respectively. Two-sided Student t test or Mann–Whitney U test was used to compare continuous variables after checking for a normal distribution with the Shapiro–Wilk test. Categorical variables were tested with Chi-square or Fisher’s exact tests, as required. To test the IOP and OHMs changes during follow-up and differences between study groups, the repeated measures ANOVA (with the Greenhouse–Geisser correction) was used. To handle missing data, we conducted both per-protocol (PP) and a last observation carried forward (LOCF) analyses. The cumulative probability of success of surgery was tested with Kaplan–Meier survival curves, censoring patients who left the study before the end of follow-up. Conditional univariable and multivariable Cox hazard models were used to test the association between preoperative and intraoperative factors with surgery failure. Gender, age, right/left eye, glaucoma type, preoperative IOP, VF damage, and number of baseline OHMs were included as preoperative factors, whereas the surgery type, position of the surgeon, implant site, type of viscoelastic, and intraoperative complications as intraoperative factors. The martingale residuals method was used to test the validity of the proportional hazard’s prerequisites. A p value < 0.05 was considered statistically significant. 3. Results Two hundred thirty-nine eyes of 239 patients from nine centers were analyzed, including 144 (60.2%) in the XEN alone group and 95 (39.8%) in the XEN+Phaco group. Of them, 87 eyes completed the 36 months of follow-up, including 53 and 34 in the XEN alone and XEN+Phaco groups, respectively. A total of 152 patients dropped out of follow-up before 36 months. Among them, five patients died before the end of follow-up, 43 patients ended follow-up because of the COVID-19 pandemic, eight patients underwent an additional glaucoma surgery, one patient developed endophthalmitis that caused the end of follow-up, and 95 patients ended their follow-up for unconfirmed/unknown reasons. Table 1 summarizes the demographic and clinical characteristics of the patients enrolled. Table 1Demographic and clinical characteristics. All Patients(n = 239)XEN Alone(n = 144)XEN+Phaco(n = 95)p Value Age, median (IQR a) 72 (65–78)73 (62–79)72 (68–77)0.57GenderMF133 (55.6%)106 (44.3%)77 (53.4%)67 (46.5%)56 (58.9%)39 (41.0%)0.46EthnicityCaucasian239 (100%)144 (100%)95 (100%)-Systemic conditionsDiabetesHypertensionAutoimmune diseases31 (12.9%)112 (77.7%)14 (5.8%)14 (9.7%)66 (45.8%)8 (5.5%)17 (17.9%)46 (48.4%)6 (6.3%) Type of glaucoma 0.28POAG bPXFG cSteroid inducedNot reported219 (91.6%)16 (6.7%)3 (1.2%)1 (0.4%)133 (92.3%)8 (5.5%)3 (2.0%)-86 (90.5%)8 (8.4%)-1 (1.0%) BCVA d, median (IQR a) 0.5 (0.2–0.8)0.8 (0.5–0.9)0.5 (1.0–0.7)<0.001 IOP e, median (IQR a) 23 (20–26)24 (21–26)23 (20–26)0.37 N of drugs, median (IQR a) 3 (2–3)3 (2–3)3 (2–3)0.07 Endothelial count, median (IQR a) 2120(1870–2460)2118(1875–2376)2224(1870–256)<0.001 Lens state <0.001PhakicPseudophakic130 (54.4%)109 (45.6%)35 (24.3%)109 (75.7%)95 (100.0%)- Previous surgery <0.001NonePhacoSLT f/ALT g*Other procedures124 (51.8%)109 (45.6%)5 (2.1%)4 (1.6%)33 (22.9%)109 (75.7%)4 (2.7%)4 (2.7%)94 (98.9%)-1 (1.0%)- Visual field damage MD h (dB), median (IQR a)−11(−18–−5.25)−12(−18–−6)−10(−16–−5)0.24Better than −6 dB−6 to −12 dBWorse than −12 dBNot reported56 (23.4%)63 (26.4%)103 (43.1%)17 (7.1%)32 (22.2%)32 (22.2%)67 (46.6%)13 (9.0%)24 (25.3%)31 (32.6%)36 (37.9%)4 (4.2%)0.18 C/D i ratio, median (IQR a) 0.7 (0.6–0.8)0.7 (0.6–0.8)0.7 (0.6–0.8)0.48a IQR, interquartile range; b POAG, primary open angle glaucoma; c PXFG, pseudoexfoliation glaucoma; d BCVA, best corrected visual acuity; e IOP, intraocular pressure; f SLT, selective laser trabeculoplasty; g ALT, argon laser trabeculoplasty; h MD, mean deviation; i C/D, cup to disc. * Performed as standalone procedure or in patients with history of previous procedures. Demographic and clinical characteristics. a IQR, interquartile range; b POAG, primary open angle glaucoma; c PXFG, pseudoexfoliation glaucoma; d BCVA, best corrected visual acuity; e IOP, intraocular pressure; f SLT, selective laser trabeculoplasty; g ALT, argon laser trabeculoplasty; h MD, mean deviation; i C/D, cup to disc. * Performed as standalone procedure or in patients with history of previous procedures. The median (IQR) age of the patients was 72 (65–78) years, and the distribution of genders was balanced (44.3% females and 55.6% males). More than 90% of all the patients included were affected by POAG, without significant differences in the percentage of other types of glaucoma between the study groups (p = 0.28). Based on VF damage, 56 (23.4%), 63 (26.4%), and 103 (43.1%) eyes showed early, moderate, and severe glaucoma, respectively. The median (IQR) VF mean deviation (MD) was −11.0 (−18.0 to −5.2) dB. 3.1. Intraocular Pressure and Ocular Hypotensive Medications IOP and OHMs over the follow-up are depicted in Figure 1. Boxplot showing the intraocular pressure (IOP) and number of ocular hypotensive medications (OHMs) at each timepoint of the follow-up for all patients (a) and for the XEN alone and XEN+Phaco groups (b). ns = not significant. Over the follow-up period, mean preoperative IOP decreased from a median (IQR) of 23 (20–26) mmHg at baseline to 14.0 (12.0–16.0) mmHg at 12 months, 15 (12.0–16.2) mmHg at 24 months, and 15.0 (12.0–17.5) mmHg at 36 months (p < 0.01). Using LOCF, the analysis yielded same median values of median IOP except for at 24 and 36 months (14 mmHg with LOCF and 15 mmHg with PP) (Figure S1 and Table S1). In addition, the total range of IOP measurements at 36 months between LOCF (6 to 27 mmHg) and PP (7 to 26 mmHg) showed negligible differences. Considering the two different study groups, no differences were found at any time point between IOP achieved with XEN and XEN+Phaco in the PP analysis. The LOCF analysis per group showed comparable results at each follow-up timepoint with a maximum difference of 1 mmHg, except for the XEN+Phaco group at 36 months, where the difference was 2 mmHg between the two analyses (14 mmHg with LOCF and 16 mmHg with PP) (Figure S1 and Table S1). At month 36 the IOP reduction was −34.1 ± 20.1%, without statistically significant differences between the percentages achieved in the XEN alone (−36.9 ± 19.6%) and XEN+Phaco (−29.9 ± 20.4%) groups, p = 0.4. The scatterplot in Figure 2 shows depicts the IOP reduction as a function of preoperative IOP and the number of OHMs at 36 months. Scatterplot comparing IOP at baseline compared to the IOP at month 36 and the number of ocular hypotensive medications (LOCF analysis). Each point represents one eye. The IOP thresholds at month 36 are represented by the horizontal gray lines. The percentage levels of IOP reduction at month 36 in comparison to preoperative IOP are shown by the black lines. Eyes without IOP data are not displayed. IOP, intraocular pressure; OHM, ocular hypotensive medications. Differences between PP and LOCF analyses are reported in Figure S2. Month 36 saw 71 (81.6%), 52 (59.7%), and 36 (41.3%) eyes achieving reductions in preoperative IOP of at least 20%, 30%, and 40%, respectively. The percentages were slightly lower when using LOCF analysis: 177 (74.0%), 152 (63.6%), and 124 (51.8%), respectively. The IOP at 36 months was ≤21 mmHg in 79 (90.8%) eyes, ≤18 mmHg in 70 (80.4%) eyes, ≤15 mmHg in 51 (58.6%) eyes, and ≤12 mmHg in 24 (27.5%) eyes. The corresponding values for LOCF were 229 (96.8%), 213 (89.1%), 158 (66.1%), and 58 (24.2%) eyes. Greater IOP reduction was achieved in patients with higher preoperative IOP ranging from −20.0% (−23.3–−14.1%) in eyes with IOP ≤ 15 mmHg to 62.5% (−65.0–−55.0%) in eyes with IOP ≥ 35 mmHg. However, the number of patients belonging to both ends of the ranges is small (Figure S3). Complete data on ocular hypotensive medications (OHMs) were available only for 52 patients at 36 months of follow-up. The mean number of OHMs was significantly lowered from 2.7 (0.95) at baseline to 0.94 (1.10) at 36 months (p < 0.001), without significant differences at any timepoint. With LOCF, the figures were comparable until 12 months of follow-up. Thereafter, LOCF showed slightly lower values of number of needed OHMs (0.64 vs. 0.94) (Figure S4 and Table S2). The per-group LOCF analysis showed comparable values for the XEN+Phaco group. Subtle differences could be found in the XEN group where at 36 months the LOCF and PP values were 0.67 and 1.06 respectively. A reduction in the number of eyes treated with 3 or 4 OHMs was observed over time, decreasing from 54.5% at baseline to 4.5% at 36 months. Notably, only 1 patient received 4 OHMs throughout the study (Figure S5). At 36 months, there were 117 (71.5%) OHM-free eyes (67.7% with the LOCF), including those treated with topical and systemic drugs. Additionally, among the patients with available data, the percentage of patients who received subsequent treatment with oral systemic carbonic anhydrase inhibitors decreased considerably from 84 (35.1%) to 0 (0.0%) (p < 0.001). 3.2. Effectiveness According to the success definition, 161 (67.3%) eyes achieved overall success at the last available follow-up over 36 months. Of those, 106 (65.8%) eyes were classified as complete success and 55 (34.1%) as qualified success. Figure 3 depicts the Kaplan–Meier survival curves, illustrating the probability of success over time for the entire study sample (Figure 3A) and for the study groups (Figure 3B). Kaplan–Meier survival curves illustrating the overall survival rates (A) and the survival rates for eyes treated with XEN alone and XEN+Phaco (B) and multivariate Cox proportional hazard ratios with 95% confidence intervals (CIs) for preoperative (C) and intraoperative (D) factors predictive of surgical failure. PXFG, pseudoexfoliation glaucoma; POAG, primary open angle glaucoma; VF, visual field; SN, superonasal. The XEN alone [69.4%, with 66 (66.0%) being complete success] and in the XEN+Phaco groups [64.2%, with 40 (68.8%) being complete success] showed comparable overall success rates (p = 0.07). Among patients who adhered the success definition, 48 eyes reached 36 months of follow-up. At the end of the study, 44 were classified as overall success (91.6%) without statistically significant differences found between study groups. On the contrary, among patients who did not complete the follow-up, at their last available follow-up visit, 66 were classified as complete success, 25 as qualified success, and 61 as failure. We further analyzed survival and success rates using various IOP thresholds: <12 mmHg, 15 mmHg, and 21 mmHg (Figure S6). At 36 months, success probabilities were similar between groups for the <12 mmHg threshold (XEN alone: 0.15, 95% CI: 0.09–0.25; XEN+Phaco: 0.07, 95% CI: 0.03–0.18, p = 0.56). However, for the <15 mmHg threshold, the XEN alone group had a significantly higher success rate (0.48, 95% CI: 0.38–0.61) compared to XEN+Phaco (0.27, 95% CI: 0.17–0.43, p = 0.041). When the threshold was set to <21 mmHg, both groups showed higher success probabilities (XEN alone: 0.66, 95% CI: 0.57–0.78; XEN+Phaco: 0.61, 95% CI: 0.49–0.76, p = 0.63) without significant differences. A total of 78 (32.6%) eyes met the surgery failure criteria: one eye showed clinical hypotony, eight eyes needed an additional glaucoma procedure (one required cyclophotocoagulation, one required an additional XEN45 implant, four required trabeculectomy, one required a glaucoma drainage device, and one required a glaucoma micro shunt). Seven surgical revisions were performed, while 62 eyes did not achieve a sufficient IOP decrease. The univariate and multivariate analyses (Figure 3) of factors associated with surgery failure showed that neither preoperative nor postoperative factors influence the success of the surgery. 3.3. Safety Table 2 displays the intra- and postoperative complications that occurred during the follow-up, with the latter grouped by early (on or before month 1) and late (after month 1) events. Table 2Early and late complications. Early(Before Month 1)Late(After Month 1) All Patients(n = 239)XEN Alone(n = 144)XEN+Phaco(n = 95)p ValueAll Patients(n = 239)XEN Alone(n = 144)XEN+Phaco(n = 95)p Value Corneal edema5 (2.1%)2 (1.4%)3 (3.1%)0.249 (3.7%)5 (3.5%)4 (4.2%)0.07 Corneal dellen0 (0.0%)0 (0.0%)0 (0.0%)9 (3.7%)4 (2.7%)5 (5.2%) Shallow AC a17 (7.1%)10 (6.9%)7 (7.4%)0 (0.0%)0 (0.0%)0 (0.0%) Hyphema12 (5.0%)5 (3.5%)7 (7.4%)0 (0.0%)0 (0.0%)0 (0.0%) Iritis0 (0.0%)0 (0.0%)0 (0.0%)7 (2.9%)4 (2.7%)3 (3.1%) AC a flare0 (0.0%)0 (0.0%)0 (0.0%) 3 (1.6%)2 (1.4%)1 (1.0%) XEN45 blocked lumen16 (6.7%)7 (4.8%)9 (9.5%)12 (6.1%)5 (3.5%)7 (7.4%) Dislocated device0 (0.0%)0 (0.0%)0 (0.0%)2 (0.8%)1 (0.7%)1 (1.0%) Conjunctival tear0 (0.0%)0 (0.0%)0 (0.0%)2 (0.8%)1 (0.7%)1 (1.0%) Leak/dehiscence5 (2.1%)3 (2.1%)2 (2.1%)0 (0.0%)0 (0.0%)0 (0.0%) Conjunctival erosion0 (0.0%)0 (0.0%)0 (0.0%)3 (1.2%)2 (1.4%)1 (1.0%) Choroidal detachment29 (12.3%)14 (9.7%)15 (15.7%)2 (0.8%)2 (1.4%)0 (0.0%) Hypotony maculopathy11 (4.6%)6 (4.2%)5 (5.2%)5 (2.1%)3 (2.1%)2 (2.1%) Macular edema0 (0.0%)0 (0.0%)0 (0.0%)9 (3.7%)4 (2.7%)5 (5.2%) Diplopia0 (0.0%)0 (0.0%)0 (0.0%)2 (0.8%)1 (0.7%)1 (1.0%) Ptosis0 (0.0%)0 (0.0%)0 (0.0%)3 (1.2%)1 (0.7%)2 (2.1%)Serious complications Blebitis0 (0.0%)0 (0.0%)0 (0.0%)-2 (0.8%)1 (0.7%)1 (1.0%)- Endophthalmitis0 (0.0%)0 (0.0%)0 (0.0%)1 (0.4%)1 (0.7%)0 (0.0%)a AC, anterior chamber. Early and late complications. a AC, anterior chamber. Each eye may have experienced single or multiple complications during follow-up. Of the study population, nonserious AEs and SAEs were recorded in 57 (23.8%) and three (1.2%) patients, respectively. One hundred forty-six (61.1%) of the eyes experienced no intraoperative complications, whereas 64 (26.7%) eyes had mild bleeding, 29 (12.1%) had hyphema (Grade I), [10] and one (0.4%) eye had conjunctival tears. Regarding the postoperative complications, there were 91 eyes (38.1%) with at least one early complication and 56 eyes (23.4%) with at least one late complication. More than one postoperative complication occurred in 42 (17.5%) eyes, either during or after surgery. The frequency of choroidal detachment was the highest [29 eyes (12.3%) and two eyes (0.8%) in the early and late follow-up period, respectively]. The majority of complications were self-limiting or treated without consequences on visual function. Among serious complications, two eyes (0.8%) with blebitis were registered at 6 months (effectively treated without clinical consequences), whereas one case of endophthalmitis was register at 18 months. Other cases of hypotony were mild and not clinically significant. The subgroup analysis for rates of complications showed no difference in the early and late phases of follow-up between the XEN alone and the XEN+Phaco groups. Additional procedures performed during the study follow-up are reported in Table 3. Table 3Additional procedures.Procedure *, n (%)Total, n (%)(n = 239)Needling Alone +MMC a +5FU b +Corticosteroid +Lidocaine27 (11.3%)18 (7.5%)14 (5.8%)7 (2.9%)2 (0.8%)Manual subconjunctival mobilization28 (11.7%)Digital massage19 (7.9%)XEN45 removal and reimplant4 (1.6%)Bleb drainage + contact lens1 (0.4%)Other procedures Laser for luminal obstruction Conjunctival Suture IOL repositioning + reimplantation Anterior chamber refill with viscoelastic Trabeculectomy Glaucoma drainage device Glaucoma micro shunt Cyclophotocoagulation Second XEN45 implant1 (0.4%)1 (0.4%)1 (0.4%)1 (0.4%)4 (1.6%)1 (0.4%)1 (0.4%)1 (0.4%)1 (0.4%)a MMC, mitomycin-C; b 5-fluorouracil. * During follow-up, eyes may have had treatment with a single procedure, multiple treatments, or a combination of procedures. Additional procedures. a MMC, mitomycin-C; b 5-fluorouracil. * During follow-up, eyes may have had treatment with a single procedure, multiple treatments, or a combination of procedures. During follow-up, 92 (38.5%) eyes needed at least one additional procedure. A total of 89 needlings were done on 55 (23.0%) eyes at least once throughout the follow-up period but no later than the first year. Thirty eyes required one needling, eighteen eyes required two, and two and five eyes required three and four needlings, respectively. In both XEN and XEN+Phaco groups, there were similar numbers of eyes that needed needlings [32 (13.2%) and 23 (9.6%), p = 0.5]. 4. Discussion This multicenter, prospective, and observational study centered on the XEN-GTR was conducted to evaluate the efficacy and safety outcomes over a 36-month period following the implantation of XEN45, either as a standalone procedure or in conjunction with phacoemulsification. Our findings demonstrate that both XEN45 implantation alone and in combination with phacoemulsification resulted in significant reductions in intraocular pressure (IOP) and a decreased requirement for ocular hypotensive medications (OHMs) in glaucoma patients over a long-term follow-up. Over half of the eyes that concluded the study attained an IOP ≤ 15 mmHg at the conclusion of the follow-up period, with a mean reduction of 34.1%. Other reports exceeding 12 months of follow-up reported IOP reductions ranging from 27.8% and 29.3% at 24 months [1,11,12] to 37% at 36 months [2]. Our report is thus in line with what others have previously reported and further confirms the stability of IOP control over time and beyond the first year of surgery. Additionally, more than 50% of eyes did not require additional medical therapy to control IOP at the end of the follow-up with a mean number of OHMs of 0.9, slightly lower compared to that reported by Reitsamer et al. [1], whose patients started with a comparable number of medications (2.5 vs. 2.7 in the present study). The overall success rate observed in our study was 68.1%. In our first report at 12 months of follow-up, the rate was 70.7%. This small difference suggests that the surgical effect of XEN45 combined or not with Phaco may last over an extended period in some patients. The success rate that we found was similar to that reported by Gillmann et al. (68.4%) for the same follow-up period of 36 months [2]. However, they used IOP ≤ 18 mmHg as a threshold instead of <18 mmHg used by our group. For this reason, comparisons of success rates should be made with caution. Because of the variability in the definition of surgical success across various studies and the relative meaning of success in given patients, we also repeated the analysis with IOP < 12, <15 mmHg, and <21 mmHg, keeping the ≥20% IOP reduction in line with most updated recommendations [6]. With the more stringent < 12 mmHg threshold, the overall probability of success considerably decreases to 29.2% (31.1% and 25% for XEN alone and XEN+Phaco, respectively). For the <15 mmHg threshold, the overall success rate remained clinically significant at 57.3% (63.1% and 48.4% for XEN alone and XEN+Phaco, respectively). Increasing the threshold to ≤21 mmHg led to a higher success rate of 74.0% (75.6% and 71.5% for XEN alone and XEN+Phaco, respectively). Regarding surgical failures, finding predictors may clinically translate into better tailored treatments for patients eligible for XEN or XEN+Phaco surgery. In our previous report at 12 months of follow-up [4], we found preoperative IOP < 15 mmHg and the temporal position of the surgeon to be significantly associated with surgery failure both in the univariate and multivariate analyses. On the contrary, no intraoperative or postoperative variables were found to be associated with surgery failure over 36 months of follow-up. The lack of identifiable factors associated with surgical failure at 3 years compared to 1 year may suggest a convergence of outcomes over time, reflecting and further supporting the long-term stability and efficacy of XEN implantation in selected patients. This may be further supported by the finding that the highest percentage of failures was registered during the first 12 months of follow-up (50%), followed by 37.1% between 12 and 24 months, and 12.8% up to 36 months, with a similar decreasing trend also previously described [2]. These observations may be attributed to several elements: (I) dynamics of bleb formation and stabilization; (II) suboptimal IOP control, especially in the first postoperative period; and (III) surgical complications. With respect to the first two points, several molecular processes underlie conjunctival fibrosis, from the release of proinflammatory cytokines to induce fibroblast proliferation and extracellular matrix remodeling [13,14]. Despite the widespread use of antifibrotic agents such us MMC and 5-fluorouracil in glaucoma bleb-forming surgeries, these processes may result in the formation of scarring and fibrotic blebs, with a consequent IOP increase, particularly in the first months of follow-up [15]. Lastly, regarding surgery complications, we registered a low number of postoperative complications with the highest frequency noted early during the follow-up (